NIDAN (NIDAN) fundamentals
NIDAN is a listed company, part of the Healthcare Services sector, listed on the NSE as NIDAN (ISIN INE0J6L01013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What NIDAN does
Nidan Laboratories and Healthcare Limited is an India-based company. The Company is engaged in providing diagnostic services including pathology, radiology, cardiology, and neurology. Its laboratory tests offer a range of over 6000 clinical laboratory tests and profiles, which are used to provide diagnostic services for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease using technological advanced machines, prenatal screening, to screening for hormonal imbalance, nutritional deficiencies, and tracking lifestyle disorders. Its services include computed tomography (CT) scans, X-radiation (X-ray), pathology, cardio, magnetic resonance imaging (MRI), sonography, outpatient department (OPD) and others. Its lab tests include CT Lower Limb Arteriography And Venography, CT Whole Spine, CT Abdomen Angiography, CT Lumber Spine, CT Calcium Scoring, Dry Film D12, CT Extra Report and others.
Valuation and market data
| Last close | ₹13.50 |
|---|---|
| Market capitalisation | ₹19 crore |
| Enterprise value | ₹21 crore |
| P/E (TTM) | 3.41 |
| Price to book | 0.28 |
| Price to sales (TTM) | 0.18 |
| Book value per share | ₹48.90 |
| Dividend yield | 0.00% |
| Sector | Healthcare Services |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹27 crore | ₹2 crore | ₹2 crore | 0.00 |
| Mar 2025 | ₹27 crore | ₹3 crore | ₹2 crore | 1.42 |
| Mar 2024 | ₹27 crore | ₹-2 crore | ₹-3 crore | -2.33 |
| Mar 2023 | ₹28 crore | ₹5 crore | ₹4 crore | 2.55 |
| Mar 2022 | ₹30 crore | ₹5 crore | ₹3 crore | 2.32 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 57.0% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 43.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.